Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects

Table of Contents:
1. Blood banking and transfusion medicine – the field, the discipline and the industry 2. Quality principles in Transfusion medicine 3. Regulatory issues in transfusion medicine 4. Role of the physician in the blood center 5. Blood donor, donation process and technical aspects of blood collection 6. Apheresis blood component collections 7. Recipient-specific blood donations 8. Adverse donor reactions (iron) 9. Component preparation and manufacturing 10. Serologic testing of donor products 11. Overview of infectious disease testing 12. HIV screening 13. Hepatitis B screening 14. Hepatitis C screening 15. WNV screening 16. Zika screening 17. Babesia screening 18. Syphilis, HTLV and Chagas screening 19. Bacterial mitigation of platelets 20. Role of the transfusion service physician 21. Pretransfusion testing 22. Antibody identification 23. Direct antiglobulin test 24. Molecular DNA based blood group typing 25. ABO and H blood group systems 26. RH and RhAg blood group system 27. KELL and KIDD blood group systems 28. MNS AND DUFFY blood group systems 29. LEWIS, I P1Pk and Glob blood group systems 30. Other blood group systems, collections, and antigens 31. Human platelet and neutrophil antigens 32. HLA Antigens 33. Red blood cells products 34. Plasma products 35. Platelet products (to include PAS if not previously mentioned; was mentioned In the 2nd edition) 36. Cryoprecipitate and fibrinogen concentrates 37. Granulocyte products 38. Albumin and related products 39. Human immunoglobuin preparations 40. Rh immune globulin 41. Coagulation Factor products 42. Platelet rich plasma 43. Convalescent plasma, including COVID convalescent plasma 42. Nonfactor therapies for bleeding disorders 44. Blood Pharming and alternative blood production methods 45. Irradiation of blood products 44. Leukoreduction of blood products 46. CMV-safe blood products 47. Frozen blood products 48. Washed blood products 49. Volume reduced blood products 50. Pathogen reduction technologies 51. Intrauterine, Neonatal and pediatric transfusion medicine 52. Perinatal transfusion medicine 53. AutoImmune hemolytic anemias 54. Transfusion management in patients with hemoglobinopathies 55. Transfusion of Patients Undergoing Hematopoietic Stem Cell Transplantation 56. Transfusion of Patients Undergoing Solid Organ Transplantation 57. Transfusion support and hemostatic monitoring in patients connected to extracorporeal devices 58. Transfusion of patients receiving antithrombotic therapy 59. Blood transfusion in economically restricted and developing countries 60. Management of Patients Who Refuse Blood Transfusion 61. Platelet transfusion refractory patients 62. Massive transfusion 63. Patient blood management 64. Overview of adverse events and outcomes following transfusion 65. Febrile non-hemolytic transfusion reactions 66. Allergic transfusion reactions 67. Acute hemolytic transfusion reactions 68. Delayed hemolytic transfusion reactions 69. Transfusion-Associated Circulatory Overload 70. Transfusion-Related Acute Lung Injury 71. Septic transfusion reactions 72. Metabolic, hypotensive and other acute reactions and complications 73. Post transfusion purpura 74. Transfusion associated graft versus host disease 75. Transfusion related immunomodulation 76. Iron Overload 77. Transfusion transmitted diseases 78. Overview to therapeutic apheresis 79. Therapeutic plasma exchange 80. Therapeutic erythrocytapheresis 81. Therapeutic thrombocytapheresis 82. Therapeutic leukocytapheresis and adsorptive cytapheresis 83. Extracorporeal photopheresis 84. LDL apheresis 85. Immunoabsorption 86. COVID-19 & Apheresis 87. Therapeutic phlebotomy 88. Overview of cellular therapy 89. HPC products derived from bone marrow and peripheral blood 90. Cord blood banking (expansion) 91. Regenerative medicine (iPS) 92. Immunotherpy (T cells): CAR-T, TILs, gene therapy and more 93. Adverse events associated with HPC product infusion 94. Quality and regulatory issues in cellular therapy 95. Tissue banking in the hospital setting 96. Overview of the coagulation system 97. Approach to the patient with a bleeding disorder 98. Congenital thrombocytopenia 99. fetal and Neonatal alloimmune thrombocytopenia 100. Acquired neonatal thrombocytopenia 101. Bernard Soulier syndrome and other GPIb-IX-V related receptor defects 102. Glanzmann's thrombocytopenia 103. Other platelet glycoprotein disorders 104. Platelet storage-granule defects 105. Failure to release and aspirin-like defects 106. Other Platelet abnormalities 107. Acquired platelet disorders 108. Acute (childhood) ITP 109. Chronic ITP 110. Drug induced thrombocytopenia 111. Heparin induced thrombocytopenia 112. Vaccine Induced Thrombotic Immune Thrombocytopenia 113. Autoimmune lymphoproliferative syndrome 114. Hemolytic uremic syndrome 115. Thrombotic thrombocytopenic purpura 116. Antiphospholipid syndrome 117. Von Willebrand Disease 118. Hemophilia A 119. Hemophilia B 120. Congenital disorders of fibrinogen 121. Factor XIII, D α2-Antiplasmin, and Plasminogen Activator Inhibitor-1 deficiencies 122. Factor XI deficiency 123. Factor VII deficiency 124. Factor II, factor V, and factor X deficiencies 125. Bleeding disorders in pregnancy 126. Vascular bleeding disorders 127. Hemostasis in Liver Disease 128. Bleeding risks with Vitamin K deficiency 129. Bleeding risks with cardiac disease 130. Bleeding risks with renal disease 131. Bleeding risks with cancer 132. Disseminated intravascular coagulopathy 133. coagulopathy in sickle cell disease and other hemoglobiniopathies 134. COVID coagulopathy 135. Thrombosis in COVID Coagulopathy---Anticoagulation guidelines 136. Bleeding in COVID coagulopathy 137. Acquired coagulation factor inhibitors 138. Overview of purposes of hemostasis testing and common sources of error 139. Pediatric reference ranges in coagulation testing  140. Prothrombin Time 141. Activated Partial Thrombolplastin Time 142. Mixing studies 143. Coagulation Factor Testing 144. Testing of Nonfactor therapies: emicizumab 145: Testing of Nonfactor therapies: inhibitors of anticoagulant pathways (fitusiran and concizumab) 146. Specific Factor Inhibitor Testing 147. Thrombin time and Fibrinogen Evaluation 148. laboratory diagnosis of inherited von Willebrand Disease 149. Laboratory Diagnosis of Acquired von Willebrand’s Syndrome 150. Laboratory Assessment of Treatment of von Willebrand’s Disease 151. Measurement of platelet count, mean platelet volume, and reticulated platelets 152. Platelet Function Analyzer 153. thromboelastography/thromboelastometry 154. Platelet Aggregation Studies 155. Laboratory Diagnosis of Platelet Functional Defects 156. Confirmatory testing for diagnosis of platelet disorders 157. Platelets in COVID coagulopathy 158. Anti-platelet Therapy Monitoring 159. Laboratory evaluation of factor XIII deficiency 160. Fibrinolytic testing 161. Age-adjusted D-Dimer cut offs to rule out PE/ VTE 162. Laboratory techniques in fibrinolysis testing 163. Laboratory evaluation of long-term thrombophilic disorders 164. Thrombophilia testing in children 165. Antithrombin Testing 166. Protein C deficiency evaluation 167. Protein S deficiency evaluation 168. testing for Activated Protein C Resistance 169. Molecular Testing for Factor V Leiden and Prothrombin Gene Mutations in inherited thrombophilia 170. Chronic elevated levels of Factor VIII and other coagulation factors 171. Laboratory Monitoring for Heparins, fondaparinux, direct thrombin inhibitors, and oral anti-Xa medications 172: DOAC interferences in coagulation testing 173. Laboratory testing in patients receiving DOAC antidotes 174. Laboratory support for warfarin monitoring 175. Molecular testing in Coagulation 176. Acquired prothrombotic conditions 177: Ventricular assist device: anticoagulation monitoring 178. Laboratory Evaluation of Heparin-Induced Thrombocytopenia 179. Laboratory Evaluation of Thrombotic Thromcytopenic Purpura 180. D-Dimer testing in COVID coagulopathy 181. Other coagulation tests in COVID coagulopathy 182. Laboratory diagnosis of lupus anticoagulant and anti-phopholipid antibodies 183. Lupus anticoagulant testing in COVID-19 184. Circulating microparticles 185. Thrombin Generation Assays 186. Laboratory testing of contact factors 187. Contact factors and complements 188. Monitoring of new anticoagulants---inhibitors of contact factors 189. Reference ranges in transgender